Compare · NXTS vs UAN
NXTS vs UAN
Side-by-side comparison of Nexentis Technologies Inc. (NXTS) and CVR Partners LP (UAN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NXTS and UAN operate in Agricultural Chemicals (Industrials), so they compete in similar markets.
- UAN is the larger of the two at $1.01B, about 897.2x NXTS ($1.1M).
- NXTS has been more active in the news (10 items in the past 4 weeks vs 4 for UAN).
- Company
- Nexentis Technologies Inc.
- CVR Partners LP
- Price
- -
- -
- Market cap
- $1.1M
- $1.01B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Agricultural Chemicals
- Agricultural Chemicals
- Exchange
- NASDAQ
- NYSE
- IPO
- 2011
- News (4w)
- 10
- 4
- Recent ratings
- 0
- 0
UAN
CVR Partners LP
CVR Partners, LP, together with its subsidiaries, produces and distributes nitrogen fertilizer products in the United States. The company offers ammonia products for agricultural and industrial customers; and urea and ammonium nitrate products to agricultural customers, as well as retailers and distributors. CVR GP, LLC serves as the general partner of the company. CVR Partners, LP was founded in 2007 and is based in Sugar Land, Texas.
Latest NXTS
- SEC Form DEF 14A filed by Nexentis Technologies Inc.
- Nexentis: MitoCareX Progresses Toward In-Vitro Evaluation Following AI-Powered Computational Screening
- Director Kalifi Udi Ovadia was granted 3,875 units of Restricted Shares of Common Stock (SEC Form 4)
- SEC Form 10-Q filed by Nexentis Technologies Inc.
- Nexentis Technologies Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities
- SEC Form PRE 14A filed by Nexentis Technologies Inc.
- Nexentis Technologies Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- Nexentis Announces Reverse Stock Split
- Nexentis: MitoCareX Completes Initial AI-Powered Computational Screening Milestone with Boltz
- Nexentis: MitoCareX Bio Advances AI-Driven Drug Discovery Initiative with Boltz, Completing Initial Computational Screening Stage
Latest UAN
- CVR Partners LP filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by CVR Partners LP
- CVR Partners Reports Third Quarter 2026 Results
- CVR Partners Announces Revised Time for Third Quarter 2026 Earnings Conference Call
- CVR Partners to Release Third Quarter 2026 Earnings Results
- SEC Form 10-Q filed by CVR Partners LP
- CVR Partners LP filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- CVR Partners Reports Second Quarter 2026 Results
- CVR Partners to Release Second Quarter 2026 Earnings Results
- New insider Roberts Richard J. Jr. claimed ownership of 517 units of Common Units (SEC Form 3)